Russian experience of sped-up work on vaccine being studied in over 10 countries - RDIF
MOSCOW. Aug 28 (Interfax) - More than ten countries are studying Russia's experience of fast-tracking the registration of a coronavirus vaccine in case of an emergency, Kirill Dmitriev, General Director of the Russian Direct Investment Fund (RDIF), said.
"Currently, more than ten countries - RDIF partners - are studying the Russian experience for fast-tracked registration of coronavirus drugs and vaccines with proven safety, based on verified solutions such as human adenoviruses used in the Russian Sputnik V vaccine," Dmitriev told journalists on Friday.
China has "begun protecting its doctors and teachers according to the Russian template by giving the vaccine to high-risk groups," he said.
"The fast-tracked registration in China of the Sinovac coronavirus vaccine for emergency use shows that many countries have gone down Russia's path in this matter," Dmitriev said.
The Sputnik V is an adenovirus-vectored, two-component vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. The SARS-CoV-2 genetic information will be delivered into cells by a carrier vector based on another virus. The two components of the vaccine are preparations based on two different adenovirus vectors. The immunization is two-stage.